Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 8963 results
Found 8963 results.

Age Factors

Van Epps P, Matining RM, Tassiopoulos K, et al. "Older age is associated with peripheral blood expansion of naïve B cells in HIV-infected subjects on antiretroviral therapy." PLoS ONE. 2014;9(9):e107064.
Hermes A, Squires K, Fredrick L, et al. "Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women." HIV Clin Trials. 2012;13(6):308-23.
Lok JJ, Hunt PW, Collier AC, et al. "The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy." AIDS. 2013;27(13):2101-10.
Zheng L, Bosch RJ, Chan ES, et al. "Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy." Antivir. Ther. (Lond.). 2013;18(1):39-43.
Crump JA, Wu X, Kendall MA, et al. "Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study." BMC Infect. Dis.. 2015;15:12.
Crawford KW, Spritzler J, Kalayjian RC, et al. "Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir." AIDS Res. Hum. Retroviruses. 2010;26(6):635-43.
Goicoechea M, Smith DM, Liu L, et al. "Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA." J. Infect. Dis.. 2006;194(1):29-37.
Kalayjian RC, Spritzler J, Matining RM, et al. "Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction." AIDS. 2013;27(10):1563-71.

African Americans

Castillo-Mancilla JR, Cohn SE, Krishnan S, et al. "Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials." HIV Clin Trials. 2014;15(1):14-26.
Hulgan T, Robbins GK, Kalams SA, et al. "T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384." PLoS ONE. 2012;7(8):e43803.
Pereyra F, Jia X, McLaren PJ, et al. "The major genetic determinants of HIV-1 control affect HLA class I peptide presentation." Science. 2010;330(6010):1551-7.
Ribaudo HJ, Haas DW, Tierney C, et al. "Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study." Clin. Infect. Dis.. 2006;42(3):401-7.
Bruggeman LA, O'Toole JF, Ross MD, et al. "Plasma apolipoprotein L1 levels do not correlate with CKD." J. Am. Soc. Nephrol.. 2014;25(3):634-44.
Foulkes AS, Wohl DA, Frank I, et al. "Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy." PLoS Med.. 2006;3(3):e52.
Atkinson BE, Krishnan S, Cox G, Hulgan T, Collier AC. "Anthropometric differences between HIV-infected individuals prior to antiretroviral treatment and the general population from 1998-2007: the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) cohort and NHANES." PLoS ONE. 2013;8(6):e65306.
Pence BWells, Reif S, Whetten K, et al. "Minorities, the poor, and survivors of abuse: HIV-infected patients in the US deep South." South. Med. J.. 2007;100(11):1114-22.
Havers FP, Detrick B, Cardoso SW, et al. "Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings." PLoS ONE. 2014;9(4):e95164.
Ribaudo HJ, Smith KY, Robbins GK, et al. "Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis." Clin. Infect. Dis.. 2013;57(11):1607-17.
Cespedes MS, Kerns SL, Holzman RS, McLaren PJ, Ostrer H, Aberg JA. "Genetic predictors of cervical dysplasia in African American HIV-infected women: ACTG DACS 268." HIV Clin Trials. 2013;14(6):292-302.
McLaren PJ, Ripke S, Pelak K, et al. "Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans." Hum. Mol. Genet.. 2012;21(19):4334-47.

Pages